US regulators have for the first time approved a pill derived from human faeces which a late-stage study showed can reduce recurrence of the potentially deadly gut infection C. difficile in adults.
The oral therapy named Vowst was developed by Seres, a Boston-based company backed by global food giant Nestlé and the US biotech incubator Flagship Pioneering behind vaccine maker Moderna.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased